← Oncology Approval Tracker

FDA DECISION ·

Hernexeos

zongertinib · Boehringer Ingelheim

Accelerated approvalNew or expanded indicationNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with unresectable or metastatic nonsquamous NSCLC with an activating HER2 (ERBB2) tyrosine kinase domain mutation identified by an FDA-authorized test. Prior systemic therapy is no longer required.

LAMPGEN ANALYSIS

Why it matters

This expands HER2-targeted treatment to include patients without prior systemic therapy for advanced disease. Beamion LUNG-1 evaluated the untreated cohort used for this decision.

What research teams should watch

Screen for the specific HER2 kinase-domain alteration and capture treatment timing. Track the confirmatory study before drawing comparative conclusions.

PRIMARY RECORDS

Sources